Raft Of New Drugs To Learn EU Marketing Fate
Sixteen EU Marketing Applications Are Nearing The End Of The Review Process
Executive Summary
ViiV Healthcare’s “last resort” HIV drug, fostemsavir, is one of 16 new medicines that are up for an opinion by the European Medicines Agency on whether they should be authorized for use across the EU.
You may also be interested in...
World First For Advicenne’s Rare Kidney Disease Drug On The Cards
Advicenne should soon find out whether the European Medicines Agency will give its product, ADV7103, the thumbs up. Approval then wouldn’t be far off.
Second Time Lucky For Dynavax’s Hep B Vaccine In EU?
The European Medicines Agency is set to decide whether Dynavax’s “fewer dose” Heplisav-B vaccine should be authorized for use across the EU – years after the company experienced a setback with its first attempt to get the vaccine approved.
On A Roll? EU Could Follow US, China & Japan In Approving Remimazolam
Paion’s novel sedation drug, remimazolam, was approved in the US, China, and Japan this year and now the European Medicines Agency is set to decide whether it should be authorized for use across the EU.